{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T22:15:29Z","timestamp":1770761729019,"version":"3.50.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Imaging"],"DOI":"10.1038\/s44303-026-00138-x","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T07:01:18Z","timestamp":1770015678000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Accelerated and localized synucleinopathy in a hybrid mouse model: implications for positron emission tomography studies"],"prefix":"10.1038","volume":"4","author":[{"given":"Chunfang A.","family":"Xia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsiu-Ming","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Diaz Garcia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuanglong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Matzeu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mani","family":"Salarian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wouter","family":"Bruinzeel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna K.","family":"Szardenings","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,2]]},"reference":[{"key":"138_CR1","doi-asserted-by":"publisher","unstructured":"Dickson, D. W. Parkinson\u2019s disease and Parkinsonism: neuropathology. Cold Spring Harb. Perspect. Med. 2, https:\/\/doi.org\/10.1101\/cshperspect.a009258 (2012).","DOI":"10.1101\/cshperspect.a009258"},{"key":"138_CR2","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.tins.2016.09.003","volume":"39","author":"NP Visanji","year":"2016","unstructured":"Visanji, N. P. et al. alpha-Synuclein-based animal models of Parkinson\u2019s disease: challenges and opportunities in a new era. Trends Neurosci. 39, 750\u2013762 (2016).","journal-title":"Trends Neurosci."},{"key":"138_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuint.2024.105760","volume":"177","author":"S Negi","year":"2024","unstructured":"Negi, S., Khurana, N. & Duggal, N. The misfolding mystery: alpha-synuclein and the pathogenesis of Parkinson\u2019s disease. Neurochem. Int. 177, 105760 (2024).","journal-title":"Neurochem. Int."},{"key":"138_CR4","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1007\/s12035-012-8327-0","volume":"47","author":"T Yasuda","year":"2013","unstructured":"Yasuda, T., Nakata, Y. & Mochizuki, H. alpha-Synuclein and neuronal cell death. Mol. Neurobiol. 47, 466\u2013483 (2013).","journal-title":"Mol. Neurobiol."},{"key":"138_CR5","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/35072550","volume":"2","author":"MF Beal","year":"2001","unstructured":"Beal, M. F. Experimental models of Parkinson\u2019s disease. Nat. Rev. Neurosci. 2, 325\u2013334 (2001).","journal-title":"Nat. Rev. Neurosci."},{"key":"138_CR6","doi-asserted-by":"publisher","unstructured":"Khan, E., Hasan, I. & Haque, M. E. Parkinson\u2019s disease: exploring different animal model systems. Int. J. Mol. Sci. 24, https:\/\/doi.org\/10.3390\/ijms24109088 (2023).","DOI":"10.3390\/ijms24109088"},{"key":"138_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2021.676257","volume":"15","author":"R Mondal","year":"2021","unstructured":"Mondal, R., Campoy, A. T., Liang, C. & Mukherjee, J. (18) F]FDG PET\/CT studies in transgenic Hualpha-Syn (A53T) Parkinson\u2019s disease mouse model of alpha-synucleinopathy. Front. Neurosci. 15, 676257 (2021).","journal-title":"Front. Neurosci."},{"key":"138_CR8","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.3233\/JPD-240207","volume":"14","author":"A Bjorklund","year":"2024","unstructured":"Bjorklund, A. & Mattsson, B. The AAV-alpha-synuclein model of Parkinson\u2019s disease: an update. J. Parkinsons Dis. 14, 1077\u20131094 (2024).","journal-title":"J. Parkinsons Dis."},{"key":"138_CR9","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/1750-1326-4-34","volume":"4","author":"JP Daher","year":"2009","unstructured":"Daher, J. P. et al. Conditional transgenic mice expressing C-terminally truncated human alpha-synuclein (alphaSyn119) exhibit reduced striatal dopamine without loss of nigrostriatal pathway dopaminergic neurons. Mol. Neurodegener. 4, 34 (2009).","journal-title":"Mol. Neurodegener."},{"key":"138_CR10","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/nrn.2017.75","volume":"18","author":"JB Koprich","year":"2017","unstructured":"Koprich, J. B., Kalia, L. V. & Brotchie, J. M. Animal models of alpha-synucleinopathy for Parkinson disease drug development. Nat. Rev. Neurosci. 18, 515\u2013529 (2017).","journal-title":"Nat. Rev. Neurosci."},{"key":"138_CR11","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s40478-017-0416-x","volume":"5","author":"CW Ip","year":"2017","unstructured":"Ip, C. W. et al. AAV1\/2-induced overexpression of A53T-alpha-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson\u2019s disease. Acta Neuropathol. Commun. 5, 11 (2017).","journal-title":"Acta Neuropathol. Commun."},{"key":"138_CR12","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s00401-018-1892-1","volume":"136","author":"G Faustini","year":"2018","unstructured":"Faustini, G. et al. Synapsin III deficiency hampers alpha-synuclein aggregation, striatal synaptic damage and nigral cell loss in an AAV-based mouse model of Parkinson\u2019s disease. Acta Neuropathol. 136, 621\u2013639 (2018).","journal-title":"Acta Neuropathol."},{"key":"138_CR13","doi-asserted-by":"publisher","first-page":"5080","DOI":"10.1523\/JNEUROSCI.0060-19.2019","volume":"39","author":"Q Wu","year":"2019","unstructured":"Wu, Q. et al. alpha-Synuclein (alphaSyn) preformed fibrils induce endogenous alphaSyn aggregation, compromise synaptic activity and enhance synapse loss in cultured excitatory hippocampal neurons. J. Neurosci. 39, 5080\u20135094 (2019).","journal-title":"J. Neurosci."},{"key":"138_CR14","doi-asserted-by":"publisher","first-page":"139","DOI":"10.14802\/jmd.19046","volume":"12","author":"HK Chung","year":"2019","unstructured":"Chung, H. K., Ho, H. A., Perez-Acuna, D. & Lee, S. J. Modeling alpha-synuclein propagation with preformed fibril injections. J. Mov. Disord. 12, 139\u2013151 (2019).","journal-title":"J. Mov. Disord."},{"key":"138_CR15","doi-asserted-by":"publisher","first-page":"E8284","DOI":"10.1073\/pnas.1710442114","volume":"114","author":"P Thakur","year":"2017","unstructured":"Thakur, P. et al. Modeling Parkinson\u2019s disease pathology by combination of fibril seeds and alpha-synuclein overexpression in the rat brain. Proc. Natl. Acad. Sci. USA 114, E8284\u2013E8293 (2017).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"138_CR16","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.3233\/JPD-223452","volume":"12","author":"A Bjorklund","year":"2022","unstructured":"Bjorklund, A., Nilsson, F., Mattsson, B., Hoban, D. B. & Parmar, M. A combined alpha-synuclein\/fibril (SynFib) model of Parkinson-like synucleinopathy targeting the nigrostriatal dopamine system. J. Parkinsons Dis. 12, 2307\u20132320 (2022).","journal-title":"J. Parkinsons Dis."},{"key":"138_CR17","first-page":"323","volume":"3","author":"C Loane","year":"2011","unstructured":"Loane, C. & Politis, M. Positron emission tomography neuroimaging in Parkinson\u2019s disease. Am. J. Transl. Res. 3, 323\u2013341 (2011).","journal-title":"Am. J. Transl. Res."},{"key":"138_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2025.108005","volume":"139","author":"KO Hauer","year":"2025","unstructured":"Hauer, K. O. et al. CSF markers of neuroinflammation, synaptic dysfunction and [(18)F]DOPA-PET in Parkinson\u2019s disease. Parkinsonism Relat. Disord. 139, 108005 (2025).","journal-title":"Parkinsonism Relat. Disord."},{"key":"138_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.crad.2025.107038","volume":"89","author":"S Li","year":"2025","unstructured":"Li, S. et al. Characteristics of the 18F-fluorodeoxyglucose ((18)F-FDG) and [(18)F] 9-fluoropropyl-(+)-dihydrotetrabenazine ((18)F-FP-DTBZ) positron emission tomography (PET) in patients with cognitive impairment in Parkinson\u2019s disease. Clin. Radiol. 89, 107038 (2025).","journal-title":"Clin. Radiol."},{"key":"138_CR20","doi-asserted-by":"publisher","unstructured":"Lee, H. et al. Synthesis and evaluation of a (18)F-labeled ligand for PET imaging of colony-stimulating factor 1 receptor. Pharmaceuticals 15, https:\/\/doi.org\/10.3390\/ph15030276 (2022).","DOI":"10.3390\/ph15030276"},{"key":"138_CR21","doi-asserted-by":"publisher","unstructured":"Salarian, M. et al. Evaluation of [(18)F]JNJ-CSF1R-1 as a positron emission tomography ligand targeting colony-stimulating factor 1 receptor. Mol. Imaging Biol. https:\/\/doi.org\/10.1007\/s11307-025-01991-9 (2025).","DOI":"10.1007\/s11307-025-01991-9"},{"key":"138_CR22","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.nbd.2017.05.014","volume":"105","author":"H Abdelmotilib","year":"2017","unstructured":"Abdelmotilib, H. et al. alpha-Synuclein fibril-induced inclusion spread in rats and mice correlates with dopaminergic Neurodegeneration. Neurobiol. Dis. 105, 84\u201398 (2017).","journal-title":"Neurobiol. Dis."},{"key":"138_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-38070-4","volume":"13","author":"T Ohgita","year":"2023","unstructured":"Ohgita, T. et al. Intramolecular interaction kinetically regulates fibril formation by human and mouse alpha-synuclein. Sci. Rep. 13, 10885 (2023).","journal-title":"Sci. Rep."},{"key":"138_CR24","doi-asserted-by":"publisher","unstructured":"Araujo, B. et al. Neuroinflammation and Parkinson\u2019s disease\u2014from neurodegeneration to therapeutic opportunities. Cells 11, https:\/\/doi.org\/10.3390\/cells11182908 (2022).","DOI":"10.3390\/cells11182908"},{"key":"138_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2022.864514","volume":"16","author":"R Rossi","year":"2022","unstructured":"Rossi, R., Arjmand, S., Baerentzen, S. L., Gjedde, A. & Landau, A. M. Synaptic Vesicle Glycoprotein 2A: features and functions. Front. Neurosci. 16, 864514 (2022).","journal-title":"Front. Neurosci."},{"key":"138_CR26","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13024-023-00676-7","volume":"18","author":"MT Henrich","year":"2023","unstructured":"Henrich, M. T., Oertel, W. H., Surmeier, D. J. & Geibl, F. F. Mitochondrial dysfunction in Parkinson\u2019s disease\u2014a key disease hallmark with therapeutic potential. Mol. Neurodegener. 18, 83 (2023).","journal-title":"Mol. Neurodegener."},{"key":"138_CR27","doi-asserted-by":"publisher","first-page":"e2314","DOI":"10.1212\/WNL.0000000000207748","volume":"101","author":"LC Beauchamp","year":"2023","unstructured":"Beauchamp, L. C. et al. Using (18)F-AV-133 VMAT2 PET Imaging to Monitor Progressive Nigrostriatal Degeneration in Parkinson Disease. Neurology 101, e2314\u2013e2324 (2023).","journal-title":"Neurology"},{"key":"138_CR28","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.2967\/jnumed.113.136143","volume":"55","author":"GI Warnock","year":"2014","unstructured":"Warnock, G. I. et al. Evaluation of 18F-UCB-H as a novel PET tracer for synaptic vesicle protein 2A in the brain. J. Nucl. Med. 55, 1336\u20131341 (2014).","journal-title":"J. Nucl. Med."},{"key":"138_CR29","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1074\/jbc.M008919200","volume":"276","author":"BI Giasson","year":"2001","unstructured":"Giasson, B. I., Murray, I. V., Trojanowski, J. Q. & Lee, V. M. A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly. J. Biol. Chem. 276, 2380\u20132386 (2001).","journal-title":"J. Biol. Chem."},{"key":"138_CR30","doi-asserted-by":"publisher","first-page":"20051","DOI":"10.1073\/pnas.0908005106","volume":"106","author":"KC Luk","year":"2009","unstructured":"Luk, K. C. et al. Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. Proc. Natl. Acad. Sci. USA 106, 20051\u201320056 (2009).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"138_CR31","doi-asserted-by":"publisher","first-page":"8955","DOI":"10.1021\/acs.jmedchem.6b00905","volume":"59","author":"C Warnier","year":"2016","unstructured":"Warnier, C. et al. Enabling efficient positron emission tomography (PET) imaging of synaptic vesicle glycoprotein 2A (SV2A) with a robust and one-step radiosynthesis of a highly potent (18)F-labeled ligand ([(18)F]UCB-H). J. Med. Chem. 59, 8955\u20138966 (2016).","journal-title":"J. Med. Chem."},{"key":"138_CR32","doi-asserted-by":"publisher","first-page":"878835","DOI":"10.3389\/fchem.2022.878835","volume":"10","author":"T Kaur","year":"2022","unstructured":"Kaur, T. et al. Automated synthesis of (18)F-BCPP-EF 2-tert-butyl-4-chloro-5-6-[2-(2[(18)F]fluoroethoxy)-ethoxy]-pyridin-3-ylmethoxy-2H-pyridazin-3-one for imaging of mitochondrial complex 1 in Parkinson\u2019s disease. Front. Chem. 10, 878835 (2022).","journal-title":"Front. Chem."},{"key":"138_CR33","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.nucmedbio.2009.10.005","volume":"37","author":"L Zhu","year":"2010","unstructured":"Zhu, L. et al. An improved radiosynthesis of [18F]AV-133: a PET imaging agent for vesicular monoamine transporter 2. Nucl. Med. Biol. 37, 133\u2013141 (2010).","journal-title":"Nucl. Med. Biol."},{"key":"138_CR34","doi-asserted-by":"publisher","unstructured":"Taube, J. M. et al. Multi-institutional TSA-amplified multiplexed immunofluorescence reproducibility evaluation (MITRE) study. J. Immunother. Cancer 9, https:\/\/doi.org\/10.1136\/jitc-2020-002197 (2021).","DOI":"10.1136\/jitc-2020-002197"},{"key":"138_CR35","doi-asserted-by":"publisher","unstructured":"Ni, R. Positron emission tomography in animal models of Alzheimer\u2019s disease amyloidosis: translational implications. Pharmaceuticals 14, https:\/\/doi.org\/10.3390\/ph14111179 (2021).","DOI":"10.3390\/ph14111179"}],"container-title":["npj Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s44303-026-00138-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44303-026-00138-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44303-026-00138-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T07:01:19Z","timestamp":1770015679000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s44303-026-00138-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,2]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["138"],"URL":"https:\/\/doi.org\/10.1038\/s44303-026-00138-x","relation":{},"ISSN":["2948-197X"],"issn-type":[{"value":"2948-197X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,2]]},"assertion":[{"value":"9 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7"}}